These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 38032)

  • 1. Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance?
    Naber D; Fischer H; Ackenheil M
    Commun Psychopharmacol; 1979; 3(1):59-65. PubMed ID: 38032
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroendocrinological and biochemical effects of chronic neuroleptic treatment.
    Hippius H; Ackenheil M; Müller-Spahn F
    Adv Biochem Psychopharmacol; 1985; 40():9-13. PubMed ID: 2862769
    [No Abstract]   [Full Text] [Related]  

  • 3. High plasma prolactin levels after long-term neuroleptic treatment.
    Zelaschi NM; Delucchi GA; Rodriguez JL
    Biol Psychiatry; 1996 May; 39(10):900-1. PubMed ID: 8860193
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of alpha-methyldopa and its metabolites on prolactin release: in vivo and in vitro studies.
    Wiggins JF; Sved AF; Fernstrom JD
    J Pharmacol Exp Ther; 1980 Feb; 212(2):304-8. PubMed ID: 6766188
    [No Abstract]   [Full Text] [Related]  

  • 5. Supersensitivity of pituitary dopamine receptors involved in the inhibition of prolactin secretion.
    Annunziato L; Quattrone A; Schettini G; Di Renzo G
    Adv Biochem Psychopharmacol; 1980; 24():379-85. PubMed ID: 6105788
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of depot neuroleptics on pituitary hormone secretion (author's transl)].
    Czernik A; Kleesiek K
    Nervenarzt; 1979 Aug; 50(8):527-33. PubMed ID: 43482
    [No Abstract]   [Full Text] [Related]  

  • 7. Basal and stimulated levels of prolactin, TSH, and LH in serum of chronic schizophrenic patients long-term treated with neuroleptics: relations to psychopathology.
    Naber D; Ackenheil M; Laakmann G
    Adv Biochem Psychopharmacol; 1980; 24():419-23. PubMed ID: 6105792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
    O'Keane V
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia.
    Igarashi Y; Higuchi T; Toyoshima R; Noguchi T; Moroji T
    Adv Biochem Psychopharmacol; 1985; 40():95-8. PubMed ID: 2862770
    [No Abstract]   [Full Text] [Related]  

  • 10. Defective central nervous system dopaminergic function in rats with estrogen-induced pituitary tumors, as assessed by plasma prolactin concentrations.
    Casanueva F; Cocchi D; Locatelli V; Flauto C; Zambotti F; Bestetti G; Rossi GL; Müller E
    Endocrinology; 1982 Feb; 110(2):590-9. PubMed ID: 6799276
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of prostaglandin inhibitors on pituitary and thyroid responses to thyrotropin-releasing hormone in man: PGs and pituitary-thyroid system.
    Pasargiklian E; De Rosa G; Troncone L; Modugno I; Satta MA; Maussier M
    Adv Prostaglandin Thromboxane Res; 1980; 8():1303-8. PubMed ID: 6769310
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuropharmacological intervention on the pituitary-hypothalamic relationship.
    Tuomisto J
    Ann Clin Res; 1978; 10(3):120-32. PubMed ID: 31130
    [No Abstract]   [Full Text] [Related]  

  • 13. Functional evaluation of prolactin secretion: a guide to therapy.
    Friesen H; Guyda H; Hwang P; Tyson JE; Barbeau A
    J Clin Invest; 1972 Mar; 51(3):706-9. PubMed ID: 4622109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central administration of orexin A suppresses basal and domperidone stimulated plasma prolactin.
    Russell SH; Kim MS; Small CJ; Abbott CR; Morgan DG; Taheri S; Murphy KG; Todd JF; Ghatei MA; Bloom SR
    J Neuroendocrinol; 2000 Dec; 12(12):1213-8. PubMed ID: 11106980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The two-syndrome concept and neuroendocrinology of schizophrenia.
    Crow TJ; Ferrier IN; Johnstone EC
    Psychiatr Clin North Am; 1986 Mar; 9(1):99-113. PubMed ID: 2870481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroendocrinology and schizophrenia research].
    Müller-Spahn F
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
    Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
    Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings: The effect of thyrotrophin releasing factor on the secretion of thyroid stimulating hormone and prolactin from the chicken anterior pituitary gland.
    Bolton N; Chadwick A; Scanes CG
    J Physiol; 1974 Apr; 238(1):78P-79P. PubMed ID: 4209906
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of thyrotropin releasing hormone (TRH) on the menstrual cycle in women.
    Zarate A; Schally AV; Soria J; Jacobs LS; Canales ES
    Obstet Gynecol; 1974 Apr; 43(4):487-9. PubMed ID: 4206099
    [No Abstract]   [Full Text] [Related]  

  • 20. Does neuroleptic blocking of dopamine receptors continue after chronic treatment?
    Belmaker RH; Dasberg H; Ebstein RP
    Prog Biochem Pharmacol; 1980; 16():109-18. PubMed ID: 6108567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.